abiraterone acetate

P2, N=150, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2028 --> May 2024

Patients with SPOPmut PC seem to exhibit superior oncological outcomes compared with patients with SPOPwt. Tailored risk stratification and treatment approaches should be explored in such patients.

P2, N=64, Not yet recruiting, Qian Qin

Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.

P1/2, N=102, Active, not recruiting, Epizyme, Inc. | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024

P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026

P3, N=1012, Active, not recruiting, AstraZeneca | Trial primary completion date: Apr 2025 --> Oct 2024

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

P2, N=64, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

P=N/A, N=250, Recruiting, AstraZeneca

P2, N=88, Recruiting, University of Maryland, Baltimore | Not yet recruiting --> Recruiting

P2, N=120, Not yet recruiting, Mayo Clinic

P3, N=900, Active, not recruiting, Eli Lilly and Company | Trial primary completion date: Oct 2025 --> Feb 2024

This study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.

P2, N=200, Recruiting, Zenith Epigenetics | Phase classification: P2b --> P2 | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Dec 2024

P2, N=64, Not yet recruiting, Mayo Clinic

P=N/A, N=20, Recruiting, University of Wisconsin, Madison | Trial completion date: Sep 2024 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2025

P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42

Here, we review the newly approved PARPi plus ARSI treatments within the context of the mCRPC treatment landscape, provide an overview of practical considerations for the combinations in clinical practice, highlight the importance of HRR testing, and discuss the benefits of treatment intensification for patients with mCRPC.

P=N/A, N=30, Recruiting, Sunnybrook Health Sciences Centre | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025

P1, N=7, Terminated, Pellficure Pharmaceuticals, Inc | N=48 --> 7 | Recruiting --> Terminated; Business Decision due to insufficient enrollment

In less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a "triplet systemic therapy," which consists in the combination of ADT, an ARPI and docetaxel, further improves outcomes, including survival...Combining prostate radiotherapy and intensified systemic treatment including abiraterone may be synergistic as suggested in the PEACE-1 trial...Importantly, most evidence currently available was obtained in men with de novo metastases, while for those with metastatic relapse after definitive local treatment, the role of treatment intensification is less well established. Treatment intensification is nowadays the standard of care for patients with de novo mCSPC as it leads to outcomes improvement, including survival, and the standard of care is evolving almost on a yearly basis.

P2, N=382, Active, not recruiting, MacroGenics | N=100 --> 382 | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2026 --> May 2027

P=N/A, N=1800, Completed, Bayer | Active, not recruiting --> Completed

P1, N=40, Active, not recruiting, Arvinas Androgen Receptor, Inc. | Trial primary completion date: Apr 2024 --> Jul 2024

Olaparib plus abiraterone has a manageable and predictable safety profile.

P3, N=200, Recruiting, The First Affiliated Hospital with Nanjing Medical University

PTEN LOF, identified with genomic testing, was associated with decreased survival and negative prognoses in patients with mCRPC.

P1, N=6, Completed, Aragon Pharmaceuticals, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024

P=N/A, N=979, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025

P1/2, N=30, Not yet recruiting, Rohan Garje

P2, N=214, Active, not recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Recruiting --> Active, not recruiting

P2; Recruiting --> Active, not recruiting

P2, N=30, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P2, N=30, Recruiting, Peking Union Medical College | Initiation date: Dec 2023 --> May 2024

P3, N=405, Active, not recruiting, pharmaand GmbH | Trial completion date: Mar 2024 --> Dec 2024

P3, N=8000, Not yet recruiting, University College, London

P2, N=0, Withdrawn, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=30 --> 0 | Not yet recruiting --> Withdrawn

Evidence suggests abiraterone may be superior to docetaxel as a first-line treatment for patients with IDC-P. To address these and other critical pathological attributes, this review examines the molecular pathology, genetics, treatments, and oncologic outcomes associated with CC-P, PDA, and IDC-P with the objective of creating a comprehensive resource with a centralized repository of information on PDA, IDC-P, and CC-P.

However, the combination treatment with BAY2402234 and abiraterone decreased intratumoral testosterone levels and induced apoptosis, which inhibited the growth of CWR22Rv1 xenograft tumors and patient-derived xenograft organoids. Taken together, these results establish DHODH as a key player in CRPC and as a potential therapeutic target for advanced prostate cancer.

Based on the research of the AR pathway, new drugs for the treatment of CRPC have been developed in clinical practice, such as Abiraterone and enzalutamide. Based on correlation analysis and flow cytometry, we can speculate that AFF3 can impact the sensitivity of the CRPC cell lines to the ferroptosis inducer (RSL3) by regulating ACSL4. Therefore, our findings may provide new insights into the mechanisms of drug resistance in CRPC, and AFF3 may serve as a novel prognostic biomarker in prostate cancer.

P2, N=13, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2023